Differentiation of healthy and cancerous renal cells using surface-enhanced Raman scattering
Is this your thesis?
This record came from a bulk archive import. If it’s yours, link it to your profile.
Abstract (EN)
Surface-enhanced Raman scattering is used for the differentiation of human kidney adenocarcinoma (ACHN), human kidney carcinoma (A-498) and non-cancerous human kidney embryonic cells (HEK 293). Silver nanoparticles (AgNPs) are used as substrates in the experiments. A volume of colloidal suspension containing AgNPs is added onto the cultured cells on CaF2 slide and the slide is dried at the overturned position. A number of SERS spectra acquired from the three different cell lines are statistically analyzed to differentiate the cells. Principal component analysis (PCA) combined with linear discriminate analysis (LDA) was performed to differentiate the three kidney cell types with a sensitivity and specificity of 88 % and 84 %, respectively. This study demonstrated that SERS could be used to identify renal cancers by combining this new sampling method and LDA algorithms.
Author
Sevda Mert
Institution
How to Cite
Sevda Mert (Master Thesis). Differentiation of healthy and cancerous renal cells using surface-enhanced Raman scattering, 2013, Yeditepe University.
Keywords
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Yeditepe University
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)